We are committed to serving the best interests of our shareholders.

Filter Releases
 
Press Releases
Date Title and Summary View
8/08/2017 ZEJULA is the most prescribed PARP inhibitor in U.S.; Q2 net sales totaled $26 million in first quarter of availabilityRecently opened European niraparib EAP has enrolled 200 patientsVARUBY oral launch now underway in Europe Dose-escalation o...
7/27/2017 — Takeda's Rights Include all Potential Indications for Niraparib in Japan and Rights Excluding Prostate Cancer in South Korea, Taiwan, Russia and Australia — TESARO to Receive $100...
7/25/2017 WALTHAM, Mass., July 25, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO) will announce its second-quarter 2017 financial results on Tuesday, August 8, 2017, after the close of the U.S. financial markets. TESARO's senior management team will host a conference call and live audio webcast at 4:15 p.m. ET on August 8, 2017 to discuss the Com...
6/29/2017 WALTHAM, Mass., June 29, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, is proud to support the Ovarian Cancer Research Fund Alliance (OCRFA) as the Presenting Sponsor of the 2017 Ovarian Cancer National Conference, being held July 7-9 in Chicago, IL. The OCRFA National Con...
6/28/2017 WALTHAM, Mass., June 28, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, is proud to announce Lonnie Moulder, CEO, and Mary Lynne Hedley, Ph.D., President and COO, have been named EY Entrepreneurs of the Year® in Life Sciences Development for the New England program. The awa...
6/26/2017 WALTHAM, Mass., June 26, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, is proud to support the Healthcare Businesswomen's Association (HBA) as a Corporate Partner. HBA is the leading global organization committed to furthering the advancement and impact of women in healthc...
6/07/2017 WALTHAM, Mass., June 07, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation at the Goldman Sachs 38th Annual Global Healthcare Conference, to be held June 13-15, 2017 at the Terranea Resort in Rancho Palos Verdes, California. Tim Pearson, ...
6/03/2017 Initial TOPACIO data for niraparib plus KEYTRUDA® is indicative of potentially synergistic anti-tumor activity in platinum-resistant ovarian cancerPhase 1 results for TSR-042 show anti-PD-1 activityThree posters presented during ASCO describe additional an...
5/25/2017 Investor briefing to be webcast from Chicago on June 3, 2017 at 6:15 PM CT WALTHAM, Mass., May 25, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the presentation of three ZEJULA™ (niraparib) abstracts at...
5/22/2017 WALTHAM, Mass., May 22, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the results of the ...
5/11/2017 WALTHAM, Mass., May 11, 2017 (GLOBE NEWSWIRE) -- TESARO Inc. (NASDAQ:TSRO) and Clinigen Group plc's (AIM:CLIN) ('Clinigen') Idis Managed Access division have partnered to launch a Managed Access Program (also known as an Early Access Program) in Europe for the investigational PARP 1/2 inhibitor, niraparib, for patients with r...
5/09/2017 ZEJULA™ approved by U.S. FDA for the maintenance treatment of women with recurrent ovarian cancer, regardless of BRCA or biomarker status; commercial launch underwayZEJULA added to the NCCN Clinical Practice Guidelines in Oncology Expanded development program for niraparib ...
5/01/2017 WALTHAM, Mass., May 01, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the submission of an Investigational New Drug (IND) Application for TSR-033 to the U.S. Food and Drug Administration. TSR-033 is a monoclonal antibody targeting LAG-3."The IND ...
4/27/2017 TSR-042 is the first TESARO immuno-oncology candidate to enter a registration programOngoing clinical trial expanded to enroll patients with endometrial cancerPatient-centric administration schedule with every 6 week dosing...
4/26/2017 VARUBY provides protection for delayed chemotherapy-induced nausea and vomiting (CINV) with a single dose as part of an antiemetic regimenUp to 50% of patients undergoing highly or moderately emetogenic chemotherapy experience delayed CINV even when prescribed a 5-HT3 receptor antagonist ...
4/25/2017 WALTHAM, Mass., April 25, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation in two upcoming investor conferences. The two conferences are:The Leerink Boston Biopharma Bus Tour on Wednesday, May 10, 2017....
4/25/2017 WALTHAM, Mass., April 25, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO) will announce its first-quarter 2017 financial results on Tuesday, May 9, 2017, after the close of the U.S. financial markets. TESARO's senior management team will host a conference call and live audio webcast at 4:15 p.m. ET on May 9, 2017 to discuss the Company's...
4/19/2017 ZEJULA is the first and only PARP inhibitor to be approved for the maintenance treatment of women with recurrent ovarian cancerZEJULA is the only PARP inhibitor that has demonstrated a clinically meaningful increase in PFS regardless of BRCA mutation or biomarker status...
4/07/2017 WALTHAM, Mass., April 07, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, has been recognized with two Clinical and Research Excellence (CARE) Awards. Pharma/Biotech Product Development Team of the Year was awarded to the niraparib development team, and the company also rece...
3/27/2017 TESARO, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved ZEJULA™ (niraparib), an oral, once-daily poly(ADP-ribose) polymerase (PARP) inhibitor, for the maintenance treatment of women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response (CR or PR) to platinum-based chemotherapy.
3/27/2017 Expanded niraparib ovarian cancer program intended to potentially transform the treatment of front-line ovarian cancerNew breast cancer clinical program for niraparib to address greatest area of unmet need and broader patient populationBRAVO trial no longer expected t...
3/13/2017 NATIONAL HARBOR, Md., March 13, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the presentation of secondary endpoint results from the Phase 3 ENGOT-OV16/NOVA trial of niraparib at the 2017 Society for Gynecologic Oncology (SGO) Annual Meeting on Women's Can...
3/12/2017 WALTHAM, Mass., March 12, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced two niraparib presentations at the 2017 Society for Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer, March 12 to 15, 2017, in National Harbor, Maryland. ...
2/28/2017 Niraparib NDA under review by FDA; pre-launch preparations for planned commercial launch well underwayExpanded access program (EAP) for niraparib open in U.S.; European EAP expected to open 1H 2017Positive opinion rendered for VARUBY® by the European M...
2/27/2017 WALTHAM, Mass., Feb. 27, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion for the Company's marketing authorization application (MAA) for VARUBY...
2/21/2017 WALTHAM, Mass., Feb. 21, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation in two upcoming investor conferences. The two conferences are: The Raymond James 38th Annual Institutional Investors Conference at the JW Ma...
2/14/2017 WALTHAM, Mass., Feb. 14, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO) will announce its fourth-quarter 2016 financial results on Tuesday, February 28, 2017, after the close of the U.S. financial markets. TESARO's senior management will host a conference call and live audio webcast at 4:15 p.m. ET on February 28, 2017 t...
2/02/2017 WALTHAM, Mass., Feb. 02, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation in two upcoming investor conferences. The two conferences are: The 6th Annual Leerink Partners Global Healthcare Conference ...
1/17/2017 WALTHAM, Mass., Jan. 17, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the opening of an expanded access program (EAP) in the United States for the investigational PARP inhibitor, niraparib. Through this program, niraparib is being made available for eligib...
1/11/2017 No concerns raised by FDA related to the rolapitant IV efficacy or safety profile and additional clinical studies are not requiredInvestor conference call and webcast scheduled for tomorrow at 8:30AM ET WALTHAM, Mass., Jan. 11, 2017 (GLOBE NEWSWIRE) -- ...
12/20/2016 Niraparib New Drug Application accepted for review by FDA with a PDUFA goal date of June 30, 2017Niraparib Expanded Access Program (EAP) expected to open in U.S. in January 2017 WALTHAM, Mass., Dec. 20, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO...
11/21/2016 WALTHAM, Mass., Nov. 21, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation in three upcoming investor conferences. The three conferences are: The Leerink POLARxPRESS Bus Tour at the Convene Conference...
11/15/2016 WALTHAM, Mass., Nov. 15, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that it has priced an underwritten public offering of an aggregate of 1,750,000 shares of its common stock at an offering price to the public of $135.00 per share. The gross proceeds from the offering will be approximately $236.3 mill...
11/14/2016 WALTHAM, Mass., Nov. 14, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO) announced today that it has commenced an underwritten public offering of 1,750,000 shares of its common stock. In connection with this offering, TESARO plans to grant the underwriters an option to purchase up to an additional 262,000 shares of its common stock. Citi...
11/03/2016 Niraparib rolling NDA submission to FDA complete, MAA accepted for review by EMAPre-launch planning ongoing to support four potential product launches in 2017 across U.S. and EuropePositive Phase 3 NOVA trial results presented during Presidential Symposium at ESMO 2016 ...
11/01/2016 WALTHAM, Mass., Nov. 01, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that it has completed the niraparib rolling New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for the maintenance treatment of patients with platinum-s...
10/31/2016 WALTHAM, Mass., Oct. 31, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the presentation of data from the ENGOT-OV16/NOVA trial of niraparib at the 2016 International Gynecologic Cancer Society (IGCS) Biennial Meeting in Lisbon, Portugal. These data were pre...
10/27/2016 WALTHAM, Mass., Oct. 27, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that the Marketing Authorisation Application (MAA) for niraparib has been submitted to and accepted for review by the European Medicines Agency (EMA) for the maintenance treatment of pat...
10/24/2016 WALTHAM, Mass., Oct. 24, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation in three upcoming investor conferences. The three conferences are:  The Credit Suisse 25th Annual Healthcare Conference at The Phoenician in Scotts...
10/20/2016 WALTHAM, Mass., Oct. 20, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO) will announce its third-quarter 2016 financial results on Thursday, November 3, 2016, after the close of the U.S. financial markets. TESARO's senior management will host a conference call and live audio webcast at 4:15 p.m. ET on November 3, 2016 to discuss the Comp...
10/08/2016 Simultaneous presentation of data at ESMO and publication online in the New England Journal of MedicineTESARO Investor Webcast to be Held at 7:00 PM CET / 1:00 PM EDT COPENHAGEN, Oct. 08, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSR...
9/29/2016 Collaboration enables the clinical development of niraparib in China by Zai Lab TESARO retains right to co-market in China and receives option to license up to two novel immuno-oncology programs outside ChinaWALTHAM, Mass., and SHANGHAI, China, Sept. 29, 20...
9/12/2016 WALTHAM, Mass., Sept. 12, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to niraparib for the treatment of patients with recurrent platinum-sensitive ovarian, fallopian tube, or primary peri...
9/06/2016 Phase 3 results from ENGOT-OV16/NOVA trial of niraparib accepted for oral presentation during Presidential Symposium and inclusion in ESMO Press ProgrammeTESARO to webcast Investor and Analyst Briefing on Saturday, October 8WALTHAM, Mass., Sept. 06, 2016 (GLO...
8/24/2016 WALTHAM, Mass., Aug. 24, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation in four upcoming investor conferences. The four conferences are:The Wells Fargo Global Healthcare Conference at the Westin Boston Wa...
8/04/2016 Positive Phase 3 data reported by TESARO and ENGOT from the NOVA trial of niraparib in a broad population of patients with platinum-sensitive, recurrent ovarian cancerPre-launch planning underway to support four potential product launches in 2017 across U.S. and Europe...
7/21/2016 WALTHAM, Mass., July 21, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO) will announce its second-quarter 2016 financial results on Thursday, August 4, 2016, after the close of the U.S. financial markets. TESARO's senior management will host a conference call and live audio webcast at 4:15 p.m. ET on August 4, 2016 to discuss the Company...
7/08/2016 The ENGOT-OV16/NOVA trial successfully achieved its primary endpoint of PFS in the germline BRCA mutant cohort  The ENGOT-OV16/NOVA trial successfully achieved its primary endpoint of PFS in the non-germline BRCA mutant cohort, including both the HRD-positive and overall analysis popu...
7/07/2016 WALTHAM, Mass., July 07, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) today announced the closing of its previously announced underwritten public offering of common stock.  TESARO sold 5,347,500 shares of its common stock at an offering price to the public of $81.00 per share, which included 697,500 shares of common stock sold pu...
6/30/2016 WALTHAM, Mass., June 30, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that it has priced an underwritten public offering of an aggregate of 4,650,000 shares of its common stock at an offering price to the public of $81.00 per share. The gross proceeds from the offering will be approximately $376.7 million....
6/30/2016 WALTHAM, Mass., June 30, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO) announced today that it has commenced an underwritten public offering of $300 million of its common stock. In connection with this offering, TESARO plans to grant the underwriters an option to purchase up to an additional $45 million of its common stock...
6/29/2016 The NOVA trial successfully achieved its primary endpoint of PFS in the germline BRCA mutant cohort   The NOVA trial successfully achieved its primary endpoint of PFS in the non-germline BRCA mutant cohort, including both the HRD-positive and overall analysis populations...
6/23/2016 ADELAIDE, Australia, June 23, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced nine presentations of rolapitant data at the 2016 MASCC/ISOO Annual Meeting on Supportive Care in Cancer, June 23 to 25, 2016, in Adelaide, Australia. "Delay...
6/04/2016 Rolapitant IV NDA accepted for review by FDA; PDUFA date is January 11, 2017Sufficient PFS events reached for data analysis of both cohorts of Phase 3 niraparib NOVA trial; data expected in Q2 2016IND for TSR-022 (anti-TIM-3 antibody) cleared by FDA; Phase 1 study to ...
5/19/2016 WALTHAM, Mass., May 19, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, is proud to congratulate co-founder, President and COO Dr. Mary Lynne Hedley on being named the Life Science "Entrepreneur of the Year" by the New England Venture Capital Association. The 2016 NEVY Awards cel...
5/18/2016 WALTHAM, Mass., May 18, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the presentation of five abstracts at the 2016 American Society of Clinical Oncology (ASCO) annual meeting, June 3 to June 7, 2016, in Chicago. In addition, TESARO will host an investor and analyst bri...
5/05/2016 U.S. launch of VARUBI® underway; New Drug Application (NDA) for IV formulation of rolapitant submittedNiraparib Phase 3 NOVA results anticipated in Q2 2016 are positioned to be the first data from a randomized, prospective Phase 3 trial of a PARP inhibitorNDA and...
4/27/2016
4/25/2016 WALTHAM, Mass., April 25, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the submission of an Investigational New Drug (IND) Application for TSR-022 to the U.S. Food and Drug Administration. TSR-022 is a monoclonal antibody drug candidate targeting TIM-3. ...
4/21/2016 WALTHAM, Mass., April 21, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO) will announce its first quarter 2016 financial results on Thursday, May 5, 2016, after the close of the U.S. financial markets. TESARO's senior management will host a conference call and live audio webcast at 4:15 p.m. ET on May 5, 2016 to discuss the Company's o...
4/06/2016 Janssen to develop and commercialize niraparib for patients with prostate cancer worldwide, except in JapanTESARO to receive up to $450 million in upfront and milestone payments, plus royaltiesJanssen to fund all development and commercialization related to niraparib ...
4/04/2016 WALTHAM, Mass., April 04, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the appointment of Kavita Patel, M.D., M.S., F.A.C.P. to the Company's Board of Directors. Dr. Patel has served as a Senior Fellow at The Brookings Institution, as well as a practicing physician at Joh...
3/29/2016 Goal to identify novel small molecule therapeutics against undisclosed immuno-oncology targets Partnership complements TESARO's existing immuno-oncology pipeline Goal to identify first clinical candidate in early 2017 WALTHAM, Mass. ...
3/29/2016 WALTHAM, Mass., March 29, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced it has dosed the first patient in a Phase 1, dose-escalation study of its lead anti-PD-1 monoclonal antibody candidate, TSR-042. Following identification of a dose and schedule for TSR-042, the trial i...
3/23/2016 WALTHAM, Mass., March 23, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that the Marketing Authorisation Application (MAA) for oral rolapitant has been submitted to and validated by the European Medicines Agency. Rolapitant is a substance P/neurokinin-1 (NK...
3/18/2016 WALTHAM, Mass., March 18, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, announced today it has completed its previously announced private placement of 4.4 million shares of common stock at a price of $35.19 per share. This transaction resulted in total gross proceeds to th...
3/14/2016 WALTHAM, Mass., March 14, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that it has submitted the New Drug Application (NDA) for an intravenous (IV) formulation of rolapitant to the U.S. Food and Drug Administration (FDA). Rola...
2/25/2016 U.S. commercial launch of VARUBI® (oral rolapitant) well underwayNiraparib Phase 3 NOVA results expected in Q2 2016 are positioned to be the first data from a randomized, prospective Phase 3 trial of a PARP inhibitorNew Drug Application (NDA) submission for nirap...
2/25/2016 WALTHAM, Mass., Feb. 25, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that it has entered into definitive agreements with institutional investors to sell 4.4 million shares of its common stock at $35.19 per share in a private placement, resulting in proceeds of...
2/11/2016 WALTHAM, Mass., Feb. 11, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO) will announce its fourth quarter 2015 financial results on Thursday, February 25, 2016, after the close of the U.S. financial markets. TESARO's senior management will host a conference call and live audio webcast at 4:15 p.m. ET on February 25, 2016 to ...
2/03/2016 WALTHAM, Mass., Feb. 03, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that Lonnie Moulder, CEO of TESARO, and Mary Lynne Hedley, President and COO of TESARO, will present at the Leerink Partners 5th Annual Global Healthcare Conference at the Waldorf Astoria in New York City on February 10, 2016 at 2:40 PM Ea...
1/11/2016 U.S. commercial launch of VARUBI™ (oral rolapitant) well underwayData from niraparib NOVA and QUADRA registration trials expected in Q2 2016 Niraparib New Drug Application (NDA) submission planned for 2H 2016Investigational New Drug (IN...
12/14/2015 WALTHAM, Mass., Dec. 14, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that the Company has been selected for addition to the NASDAQ Biotechnology Index (NASDAQ:NBI), effective upon market open on December 21, 2015. The NASDAQ Biotechnology Index is designed to track the...
11/16/2015 VARUBI™(rolapitant) provides extended protection for chemotherapy-induced nausea and vomiting (CINV) in the delayed phase (25-120 hours) with a single dose as part of an antiemetic regimen More than half of patients undergoing emetogenic chemotherapy may experience delayed CINV, even when prescribed a 5-HT3 receptor antagonist and a cort...
11/06/2015 WALTHAM, Mass., Nov. 6, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the presentation of three posters describing niraparib at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, November 5-9, 2015, in Boston, Massachusetts. The posters...
10/29/2015 VARUBI™ (oral rolapitant) approved by U.S. FDA; commercial launch planned for mid-November VARUBI™ added to National Comprehensive Cancer Network (NCCN) Antiemesis Guidelines with a Category 1 Level of Evidence and Consensus Patient treatment continues in the Phase 3 NOVA trial of niraparib; based upon the observed event rate, top-line ...
10/22/2015 WALTHAM, Mass., Oct. 22, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation in three upcoming investor conferences. The three conferences are:The 2015 Citi Global Healthcare Conference at the New York Palace in New York City on Wednesday, November 4 and Thursday, Nov...
10/15/2015 WALTHAM, Mass., Oct. 15, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO) will announce its third-quarter 2015 financial results on Thursday, October 29, 2015, after the close of the U.S. financial markets. TESARO's senior management team will host a conference call and live audio webcast at 4:15 p.m. ET on October 29, 2015 to provide a business...
9/24/2015 WALTHAM, Mass., Sept. 24, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the decision of the National Comprehensive Cancer Network (NCCN) to include VARUBI™ (rolapitant) in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Antiemesis Version 2.2015, a...
9/21/2015 WALTHAM, Mass., Sept. 21, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the appointment of Martin Huber, M.D., to the position of Senior Vice President and Chief Medical Officer. Dr. Huber will report to Mary Lynne Hedley, Ph.D., President and COO of TESARO, and will lead the glo...
9/02/2015 Approval Based Upon Four Trials of Patients Receiving Emetogenic Chemotherapy, Including Cisplatin, Carboplatin and Anthracycline/Cyclophosphamide-Based Regimens   VARUBI™ to Address a Potential U.S. Market Opportunity That Exceeds $1 Billion   U.S. Commercial Launch Planned for Q4 2015 WALTHAM, Mass., Sept. 2, 2015 (G...
9/01/2015 WALTHAM, Mass., Sept. 1, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation in three upcoming investor conferences. The three conferences are:The 10th Annual Citi Biotech Day at the Mandarin Oriental Hotel in New York City on Wednesday, September 9 and Thursday, Sept...
8/06/2015 U.S. FDA PDUFA action date for oral rolapitant is September 5, 2015Bioequivalence of IV and oral rolapitant successfully demonstratedData from Phase 3 NOVA trial of niraparib anticipated in Q4 2015Cash and cash equivalents totaled $354 million as of June 30, 2015 WALTHAM, Mass., Aug. 6, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an on...
7/30/2015 WALTHAM, Mass., July 30, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, and Jiangsu Hengrui Medicine Co., Ltd., a fully integrated pharmaceutical company based in China, today announced an exclusive license agreement for the development, registration, manufacture, and commercialization of rolapit...
7/23/2015 WALTHAM, Mass., July 23, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO) will announce its second-quarter 2015 financial results on Thursday, August 6, 2015, after the close of the U.S. financial markets. TESARO's senior management team will host a conference call and live audio webcast at 4:15 p.m. ET on August 6, 2015 to provide a business an...
7/13/2015 WALTHAM, Mass., July 13, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the appointment of Grant C. Bogle to the newly created position of Senior Vice President and Chief Commercial Officer. In this role, Mr. Bogle will report to Lonnie Moulder, CEO of TESARO, and will lead TESARO...
6/29/2015 WALTHAM, Mass., June 29, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced the appointment of Jeffrey H. Hanke, Ph.D., to the newly created role of Executive Vice President, Research and Development, and Chief Scientific Officer. In this position, Dr. Hanke will report to Mary Lynne ...
6/25/2015 WALTHAM, Mass., June 25, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced the presentation of six abstracts at the 2015 Multinational Association of Supportive Care in Cancer (MASCC/ISOO) Annual Meeting, June 25 to 27, 2015, in Copenhagen.Presentation Details:Efficacy and safety of ...
5/30/2015 WALTHAM, Mass., May 30, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced the successful completion of the rolapitant bioequivalence study. "The results of this study indicate that the exposure for a 185 milligram dose of intravenous rolapitant is similar to the exposure of a 200...
5/30/2015 WALTHAM, Mass. and KENILWORTH, N.J., May 30, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced a collaboration to evaluate the combination of TESARO's niraparib plus Merck's anti-PD1 therapy, KEYTRUDA® (pem...
5/20/2015 WALTHAM, Mass., May 20, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, announced today that Lonnie Moulder, CEO of TESARO, will present an overview of TESARO's business and development programs at the Jefferies 2015 Global Healthcare Conference at the Grand Hyatt hotel in New York City on Wednesd...
5/14/2015 WALTHAM, Mass., May 14, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced the results of its Annual Stockholder Meeting, which was held today at 8:30 AM Eastern Time in Waltham, Massachusetts. Garry A. Nicholson has been elected to the TESARO Board of Directors. In addition to electi...
5/13/2015 WALTHAM, Mass., May 13, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced the presentation of seven abstracts at the 2015 American Society of Clinical Oncology (ASCO) annual meeting, May 29 to June 2, 2015, in Chicago. In addition, TESARO will host an investor and analyst briefing in...
4/30/2015 Both the non-germline and germline BRCA mutation cohorts within NOVA are fully enrolled Phase 3 data from NOVA is expected in Q4 2015 Patients are now being treated within the QUADRA trial WALTHAM, Mass., April 30, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today provided an upd...
4/30/2015 Target enrollment completed for both cohorts of the niraparib Phase 3 NOVA trial; data expected in Q4 2015QUADRA trial of niraparib initiated; initial data anticipated in early 2016U.S. FDA PDUFA action date for oral rolapitant is September 5, 2015Cash and cash equivalents totaled approximately $399 million as of March 31, 2015 WALTHAM, Mass.,...
4/23/2015 WALTHAM, Mass., April 23, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced the launch of Ask About CINV, a campaign to raise awareness of chemotherapy-induced nausea and vomiting (CINV) and the importance of fostering an open dialogue about CINV among patients and their health care ...
4/22/2015 WALTHAM, Mass., April 22, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced its participation in three investor conferences during the month of May, including: The Mizuho Securities USA Third Annual Healthcare Corporate Access Day in New York City on Tuesday, May 5, 2015; T...
4/16/2015 WALTHAM, Mass., April 16, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) will announce its first-quarter 2015 financial results on Thursday, April 30, 2015, after the close of the U.S. financial markets. TESARO's senior management team will host a conference call and live audio webcast at 4:15 p.m. ET on April 30, 2015 to provide a business an...
4/14/2015 WALTHAM, Mass., April 14, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced two upcoming presentations related to its immuno-oncology portfolio. The Company will participate in the Jefferies 2015 Immuno-Oncology Summit at the Boston Harbor Hotel on April 15, 2015. Mary Lynne Hed...
4/09/2015 WALTHAM, Mass., April 9, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced the nomination of Garry A. Nicholson for election to the Company's Board of Directors. He will stand for election as an independent director at TESARO's 2015 annual meeting of stockholders, which is scheduled ...
3/31/2015 WALTHAM, Mass., March 31, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced the appointment of Joseph L. Farmer as Senior Vice President, General Counsel and Secretary. Mr. Farmer most recently served as Vice President, Chief Corporate Counsel and Assistant Secretary of Cubist Pharma...
3/09/2015 WALTHAM, Mass., March 9, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) today announced the closing of its previously announced underwritten public offering of common stock. TESARO sold 3,755,000 shares of common stock at an offering price to the public of $51.00 per share, which included 355,000 shares of common stock sold pursuant to the par...
3/05/2015 WALTHAM, Mass., March 5, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that Mary Lynne Hedley, Ph.D., President and COO of TESARO, will present at the Barclays Global Healthcare Conference at the Loews Hotel in Miami on March 11, 2015 at 2:05 PM Eastern time. A live webcast of this presentation will be accessible via the Inves...
3/03/2015 WALTHAM, Mass., March 3, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that it has priced an underwritten public offering of an aggregate of 3,400,000 shares of its common stock at a price to the public of $51.00 per share. The gross proceeds from the offering will be approximately $173.4 million. In addition, TESARO has grant...
3/02/2015 WALTHAM, Mass., March 2, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that it has commenced an underwritten public offering of $150 million of its common stock. In connection with this offering, TESARO plans to grant the underwriters an option to purchase up to an additional $22.5 million of its common stock to cover over-all...
2/19/2015 Enrollment in niraparib NOVA non-gBRCA cohort on track to complete during Q1 2015 New QUADRA trial of niraparib for the treatment of ovarian cancer to begin in Q1 2015U.S. FDA PDUFA action date for oral rolapitant is September 5, 2015Cash and cash equivalents totaled approximately $257 Million as of December 31, 2014 WALTHAM, Mass., Feb. 19, 2...
2/05/2015 WALTHAM, Mass., Feb. 5, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that Lonnie Moulder, CEO of TESARO, will present at the Leerink Global Healthcare Conference at the Waldorf Astoria in New York City on February 12, 2015 at 11:10 AM Eastern time. A live webcast of this presentation will be accessible via the Investors page ...
2/05/2015 WALTHAM, Mass., Feb. 5, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) will announce its fourth-quarter 2014 financial results on Thursday, February 19, 2015, after the close of the U.S. financial markets. TESARO's senior management team will host a conference call and live audio webcast at 4:15 p.m. ET on February 19, 2015 to discuss the Comp...
1/12/2015 -- New trial of niraparib for the treatment of ovarian cancer to begin in Q1 2015 -- HRD assay to be incorporated into Phase 3 NOVA trial of niraparib in ovarian cancer  -- Initial Phase 3 data from NOVA is expected to become available in 2015  -- U.S. FDA PDUFA action date for oral rolapitant is September 4, 2015 WALTHAM, Mass., Jan. 12, 2015 ...
12/02/2014 --Candidate Will Target Two Undisclosed Immune Checkpoints--Anti-TIM-3 Antibody Data to be Presented Today at the AACR Conference in Orlando WALTHAM, Mass. and SAN DIEGO, Dec. 2, 2014 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, and AnaptysBio, Inc., a privately-held therapeutic antibody company...
11/25/2014 WALTHAM, Mass., Nov. 25, 2014 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that Mary Lynne Hedley, Ph.D., President and COO of TESARO, will present at the 2014 Deutsche Bank BioFEST Conference on Tuesday, December 2, 2014 at 4:00 p.m. ET in Boston. A live webcast will be accessible via the Investors page of the TESARO website at ...
11/25/2014 WALTHAM, Mass., Nov. 25, 2014 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that Lonnie Moulder, CEO of TESARO, will present at the Nasdaq 31st Investor Program on Tuesday, December 2, 2014 at 10:15 a.m. GMT in London. A live webcast will be accessible via the Investors page of the TESARO website at www.tesarobio.com. An archived ...
11/20/2014 BARCELONA, November 20, 2014 - TESARO, Inc. (NASDAQ: TSRO) and Myriad Genetics (NASDAQ: MYGN) today announced a collaboration utilizing Myriad's myChoice HRD companion diagnostic (CDx) to identify tumor tissue with a deficiency in homologous recombination. Under the terms of the agreement, TESARO will utilize Myriad's test to enrich the target...
11/12/2014 WALTHAM, Mass., Nov. 12, 2014 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that Lonnie Moulder, CEO of TESARO, will present at the Jefferies 2014 Global Healthcare Conference on Wednesday, November 19, 2014 at 11:20 a.m. GMT in London. A live webcast will be accessible via the Investors page of the TESARO website at www.tesarobio...
11/05/2014 Oral Rolapitant New Drug Application (NDA) Accepted for Review by U.S. FDAEnrollment in Niraparib NOVA Trial Non-gBRCA Cohort on Track to Be Complete at Year End Anti-LAG-3 Clinical Lead Antibody Identified Cash and Cash Equivalents Totaled Approximately $296 Million as of September 30, 2014 WALTHAM, Mass., Nov. 5, 2014 (GLOBE NEWSWIRE) -- TES...
10/22/2014 WALTHAM, Mass., Oct. 22, 2014 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) will announce its third-quarter 2014 financial results on Wednesday, November 5, 2014, after the close of the U.S. financial markets. TESARO's senior management team will host a conference call and live audio webcast at 4:15 p.m. ET on November 5, 2014 to discuss the Compa...
9/29/2014 WALTHAM, Mass., Sept. 29, 2014 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today the closing of its previously announced underwritten public offering of $201.25 million aggregate principal amount of its 3.00% convertible senior notes due 2021 (the "notes"), including the notes issued pursuant to the full exercise of the underwriters' o...
9/23/2014 WALTHAM, Mass., Sept. 23, 2014 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today the pricing of $175 million aggregate principal amount of its 3.00% convertible senior notes due 2021 (the "notes") in an underwritten public offering. The size of the offering was increased from the previously announced aggregate principal amount of $165 ...
9/22/2014 WALTHAM, Mass., Sept. 22, 2014 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that, subject to market and other conditions, it intends to offer $165 million aggregate principal amount of convertible senior notes due 2021 (the "notes") in an underwritten public offering. TESARO also expects to grant the underwriters a 30-day option t...
9/08/2014 WALTHAM, Mass., Sept. 8, 2014 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced that it has submitted the New Drug Application (NDA) for oral rolapitant to the U.S. Food and Drug Administration (FDA). Rolapitant is an investigational neurokinin-1 (NK-1) receptor antagonist developed for t...
8/21/2014 WALTHAM, Mass., Aug. 21, 2014 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, announced that Lonnie Moulder, CEO, Mary Lynne Hedley, Ph.D., President and COO, and Tim Pearson, Executive Vice President and CFO of TESARO, will participate in several upcoming investor conferences during the month of Septe...
7/24/2014 WALTHAM, Mass., July 24, 2014 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced that Mary Lynne Hedley, Ph.D., President and Co-Founder of TESARO, has been appointed to the role of Chief Operating Officer. "Since the founding of TESARO in 2010, Mary Lynne has been instrumental in defi...
7/24/2014 Oral Rolapitant New Drug Application (NDA) on Track for Submission to U.S. FDAEnrollment in Niraparib NOVA Trial Non-gBRCA Cohort Expected to Be Complete at Year End Enrollment in Phase 1 Trial of Niraparib in Patients with Ewing's Sarcoma InitiatedAnti-TIM-3 Clinical Lead and Back Up Antibodies Identified Cash and Cash Equivalents Totaled Approxim...
7/10/2014 WALTHAM, Mass., July 10, 2014 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) will announce its second-quarter 2014 financial results on Thursday, July 24, 2014, after the close of the U.S. financial markets. TESARO's senior management team will host a conference call and live audio webcast at 4:15 p.m. ET on July 24, 2014 to discuss the Company's r...
6/27/2014 MIAMI, June 27, 2014 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced that three oral presentations detailing the final results from the rolapitant registration program were delivered today at the MASCC/ISOO International Symposium on Supportive Care in Cancer annual meeting in Miami. Ro...
6/01/2014 Oral Rolapitant New Drug Application (NDA) Submission on Track for Mid-2014Development Plans for Niraparib in Small Cell Lung Cancer and First-Line Ovarian Cancer Announced CHICAGO, June 1, 2014 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced that final results from three Phase 3 tr...
5/27/2014 WALTHAM, Mass., May 27, 2014 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced the appointment of Tim Pearson as Chief Financial Officer. Mr. Pearson was most recently Executive Vice President and Chief Financial Officer of Catalyst Health Solutions, Inc., where he led the finance and str...
5/27/2014 WALTHAM, Mass., May 27, 2014 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, invites investors and the general public to listen to a webcast of an investor briefing scheduled for Sunday, June 1 at 6:15 PM Central time in conjunction with the 2014 American Society of Clinical Oncology (ASCO) annual meet...
5/16/2014 WALTHAM, Mass., May 16, 2014 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced that Earl M. (Duke) Collier, Jr. has been elected to the TESARO Board of Directors. "On behalf of the Company and the entire board, I would like to thank Paul Walker for his leadership and years of service ...
5/14/2014 WALTHAM, Mass., May 14, 2014 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced the presentation of six abstracts at the 2014 American Society of Clinical Oncology (ASCO) annual meeting, May 30 to June 3, 2014, in Chicago. The presentations will include detailed results from the three Phas...
5/14/2014 WALTHAM, Mass., May 14, 2014 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that Lonnie Moulder, CEO of TESARO, and Dr. Mary Lynne Hedley, president of TESARO, will present at the UBS 2014 Global Healthcare Conference on Wednesday, May 21, 2014 at 8:00 a.m. Eastern time at the Sheraton New York Times Square Hotel. A live webcast...
5/12/2014 Achieved Primary Endpoint of Complete Response (CR) in the Delayed Period (24 to 120 Hours) Following Initiation of ChemotherapyAchieved Key Secondary Endpoints of CR in the Acute and Overall PeriodsAchieved All Secondary Endpoints, Including No Significant NauseaAdverse Event Profile Consistent with Earlier Clinical TrialsNew Drug Application (NDA...
5/01/2014 WALTHAM, Mass., May 1, 2014 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that Lonnie Moulder, CEO of TESARO, and Dr. Mary Lynne Hedley, President of TESARO, will present at the Deutsche Bank Securities 39th Annual Health Care Conference on Wednesday, May 7, 2014 at 1:30 p.m. Eastern time at the InterContinental Hotel Boston. A li...
4/30/2014 Oral Rolapitant New Drug Application on Track for Submission to U.S. FDA in Mid-2014Multiple Data Presentations Planned for the 2014 ASCO Meeting Niraparib Phase 3 BRAVO and NOVA Trials Enrolling PatientsCash and Cash Equivalents Totaled Approximately $180 Million as of March 31, 2014 WALTHAM, Mass., April 30, 2014 (GLOBE NEWSWIRE) -- TESARO, ...
4/16/2014 WALTHAM, Mass., April 16, 2014 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) will announce its first quarter 2014 financial results on Wednesday, April 30, 2014, after the close of the U.S. financial markets. TESARO's senior management will host a conference call and live audio webcast at 4:15 p.m. ET on April 30, 2014 to discuss the Company's res...
4/02/2014 WALTHAM, Mass., April 2, 2014 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced that two posters highlighting its niraparib and immuno-oncology programs will be presented at the American Association of Cancer Research (AACR) meeting, which will take place April 5-9, 2014 in San Diego, Cal...
3/13/2014 Immuno-oncology platform provides a portfolio of candidates focused on high value targets, potentially augments the value of other pipeline candidates and enhances prospects for future collaborations to advance TESARO's overall oncology strategy Potential first-in-class anti-TIM-3 antibody clinical candidate expected to be selected second-quarter 2...
3/06/2014 WALTHAM, Mass., March 6, 2014 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that Lonnie Moulder, CEO of TESARO, will present at the Barclays Global Healthcare Conference in Miami on Thursday, March 13, 2014 at 8:30 a.m. Eastern time. A live webcast will be accessible via the Investors page of the TESARO website at www.tesarobio.co...
2/19/2014 Oral Rolapitant New Drug Application on Track for Submission to U.S. FDA in Mid-2014Niraparib Phase 3 NOVA and BRAVO Trials Continue to AdvanceCash and Cash Equivalents Totaled Approximately $130 Million as of December 31, 2013 Successful Follow-On Offering Raised Approximately $94 Million in February 2014 WALTHAM, Mass., Feb. 19, 2014 (GLOBE N...
2/07/2014 WALTHAM, Mass., Feb. 7, 2014 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) will announce its fourth quarter 2013 financial results on Wednesday, February 19, 2014, after the close of the U.S. financial markets. TESARO's senior management will host a conference call and live audio webcast at 4:15 p.m. ET on February 19, 2014 to discuss the Company'...
2/05/2014 WALTHAM, Mass., Feb. 5, 2014 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that Lonnie Moulder, CEO of TESARO, and Mary Lynne Hedley, Ph.D., President of TESARO, will participate in two investment conferences in February, including: The Leerink Swann Global Healthcare Conference at the Waldorf Astoria in New York City. TESARO ...
1/29/2014 WALTHAM, Mass., Jan. 29, 2014 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that it has priced an underwritten public offering of an aggregate of 3,200,000 shares of its common stock at a price to the public of $31.50 per share. The gross proceeds from the offering will be approximately $101 million. In addition, TESARO has granted...
1/28/2014 WALTHAM, Mass., Jan. 28, 2014 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that it has commenced an underwritten public offering of $100 million of its common stock. In connection with this offering, TESARO plans to grant the underwriters an option to purchase up to an additional $15 million of its common stock to cover over-allot...
1/07/2014 WALTHAM, Mass., Jan. 7, 2014 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that Lonnie Moulder, CEO of TESARO, and Mary Lynne Hedley, Ph.D., President of TESARO, will attend the 32nd Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco. Mr. Moulder will make a presentation at the conference on T...
12/23/2013 A Phase 3 Trial in Patients Receiving Moderately Emetogenic Chemotherapy (MEC) Met the Primary Endpoint of Complete Response in the Delayed Period (24-120 Hours) Following Initiation of ChemotherapyA Phase 3 Trial in Patients Receiving Highly Emetogenic Chemotherapy (HEC) also Met the Primary Endpoint of Complete Response in the Delayed Period Foll...
11/25/2013 WALTHAM, Mass., Nov. 25, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that Lonnie Moulder, CEO of TESARO, and Mary Lynne Hedley, Ph.D., President of TESARO, will present at the 2013 Deutsche Bank BioFEST conference at the Four Seasons Hotel in Boston on Monday, December 2, 2013 at 2:15 p.m. Eastern time. A live webcast will ...
11/07/2013 Top-Line Results Expected to be Announced at Year-End 2013 from Two Phase 3 Trials of Oral RolapitantPatient Enrollment in the Third Phase 3 Trial of Oral Rolapitant Expected to Conclude at Year End; Top-Line Results Now Anticipated in Early 2014 Dose Ranging Study of Intravenous Rolapitant Expected to Complete by Year EndPatient Enrollment Ongoing...
10/24/2013 WALTHAM, Mass., Oct. 24, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) will announce its third quarter 2013 financial results on Thursday, November 7, 2013, after the close of the U.S. financial markets. TESARO's senior management will host a conference call and live audio webcast on Thursday, November 7, 2013 at 4:30 p.m. ET to discuss the C...
9/30/2013 WALTHAM, Mass., Sept. 30, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced that an open label, dose-finding and escalation study has been initiated to evaluate the pharmacokinetics, safety and tolerability of an intravenous (IV) formulation of rolapitant in healthy volunteers. Rolap...
9/29/2013 TSR-011 Identified as a Potent Dual Inhibitor of ALK and TRK KinasesPreliminary Clinical Activity Demonstrated in Patients with Several Tumors, Including ALK-Positive NSCLC Patients Previously Treated with CrizotinibPhase 2 Dose Selection and Cohort Expansion Into Patients With ALK-Positive or TRK-Mutated Tumors Anticipated to Occur by Year End ...
8/30/2013 WALTHAM, Mass., Aug. 30, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, announced that Lonnie Moulder, CEO of TESARO, and Mary Lynne Hedley, Ph.D., President of TESARO, will participate in several upcoming investor conferences during the month of September, including:Citi's 8th Annual Biotech Day...
7/25/2013 Top-Line Results from Rolapitant Phase 3 Program to be Announced by Year-End 2013Patient Enrollment Ongoing in Phase 3 Trial of Niraparib in Ovarian Cancer Phase 3 Trial of Niraparib in Breast Cancer On Track to Begin 2H 2013First TSR-011 Clinical Data Accepted for Presentation at ESMO Cash and Cash Equivalents Totaled $178 Million as of June 30, 2...
7/23/2013 WALTHAM, Mass., July 23, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced that it has initiated patient enrollment in a Phase 3 trial of niraparib, an inhibitor of poly ADP-ribose polymerase (PARP), for the treatment of ovarian cancer. This trial, referred to as NOVA, will evaluate ...
7/18/2013 WALTHAM, Mass., July 18, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) will announce its second quarter 2013 financial results on Thursday, July 25, 2013, after the close of the U.S. financial markets. TESARO's senior management will host a conference call and live audio webcast on Thursday, July 25, 2013 at 4:30 p.m. ET to discuss the Compan...
7/02/2013 WALTHAM, Mass., July 2, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that Lonnie Moulder, Chief Executive Officer, will present at the 8th Annual JMP Securities 2013 Healthcare Conference at The St. Regis Hotel in New York City on Tuesday, July 9, 2013 at 1:30 p.m. EDT. Interested parties may access a live audio webcast of t...
6/28/2013 PK Data from Drug-Drug Interaction Study Describes Lack of CYP3A4 Interactions BERLIN, June 28, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced that results from a pharmacokinetic study of rolapitant, an NK-1 receptor antagonist, were presented this morning at the Multinational...
6/04/2013 A RECIST Response Rate of 75% Was Achieved at the 300mg Dose in Patients With Platinum-Sensitive High Grade Serous Ovarian Cancer A RECIST Response Rate of 50% Was Achieved Across All Dose Levels in Patients With Platinum Sensitive Ovarian Cancer and Germline BRCA Mutations Progression Free Survival Exceeded One Year Among Platinum-Sensitive Ovaria...
6/03/2013 CHICAGO and BRUSSELS, Belgium, June 3, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, Breast International Group (BIG), a non-profit organization for academic breast cancer research groups from around the world, and the European Organization for Research and Treatment of Cancer (EORTC), an intern...
6/03/2013 CHICAGO, June 3, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, and the European Network of Gynecological Oncological Trial Groups (ENGOT), a network of national and regional clinical trial organizations, today announced a partnership for the Phase 3 clinical development of niraparib, an orally a...
5/28/2013 WALTHAM, Mass., May 28, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) invites investors and the general public to listen to a webcast of a presentation by the TESARO management team at an investor briefing on Sunday, June 2, 2013 at 6:15 p.m. Central time, in connection with the annual meeting of the American Society of Clinical Oncology (ASC...
5/22/2013 WALTHAM, Mass., May 22, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that Lonnie Moulder, Chief Executive Officer, and Mary Lynne Hedley, Ph.D., President, will present at the Deutsche Bank 38th Annual 2013 Health Care Conference at the Westin Boston Waterfront Hotel on Wednesday, May 29, 2013 at 3:30 p.m. EDT. Interested pa...
5/16/2013 Final Phase 1 Results Demonstrate Activity in Ovarian and Breast CancerPhase 3 Trial in Ovarian Cancer to Begin Enrolling Patients by Mid-YearPhase 3 Trial in Patients With Breast Cancer on Track to Initiate in 2H13 WALTHAM, Mass., May 16, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today ...
5/09/2013 WALTHAM, Mass., May 9, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced that James O. Armitage, M.D., F.A.C.P., F.R.C.P., has been elected to the TESARO Board of Directors. This election increases the number of independent directors on the Company's Board to six. Dr. Armitage is...
4/25/2013 Phase 3 Trial of Niraparib in Breast Cancer to be Initiated in the Second Half of 2013Phase 3 Trial of Niraparib in Ovarian Cancer on Track to Begin Enrolling Mid-2013Top-Line Results of Rolapitant Phase 3 Program to be Announced in the Second Half of 2013Fifth Dose Level Achieved in Phase 1/2 Clinical Trial of TSR-011Net Cash Position Totaled Appr...
4/17/2013 WALTHAM, Mass., April 17, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) will announce its first quarter 2013 financial results on Thursday, April 25, 2013, after the close of the U.S. financial markets. TESARO's senior management will host a conference call and live audio webcast on Thursday, April 25, 2013 at 4:30 p.m. ET to discuss the Comp...
3/28/2013 WALTHAM, Mass., March 28, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that Mary Lynne Hedley, Ph.D., President and Chief Scientific Officer, will present at the 20th Annual Future Leaders in the Biotech Industry Conference at the Millennium Broadway Hotel and Conference Center in New York City on Friday, April 5, 2013 at 1:3...
3/05/2013 WALTHAM, Mass., March 5, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today the closing of its previously announced underwritten public offering of common stock. The total number of shares of common stock sold was 5,428,000, composed of 4,720,000 shares of common stock initially offered and an additional 708,000 shares of common st...
2/28/2013 WALTHAM, Mass., Feb. 28, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that it has priced an underwritten public offering of an aggregate of 4,720,000 shares of its common stock at a price to the public of $18.00 per share. The gross proceeds from the offering will be approximately $85 million upsized from the previously annou...
2/25/2013 WALTHAM, Mass., Feb. 25, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that it has commenced an underwritten public offering of $75 million of its common stock. In connection with this offering, TESARO plans to grant the underwriters an option to purchase up to an additional $11,250,000 shares of its common stock to cover over...
2/14/2013 Niraparib to be Advanced in a Phase 3 Pivotal Trial for Ovarian CancerEnrollment Continues in the Global Registration Program for RolapitantAchieved Third Dose-level in a Phase 1/2 Clinical Trial of TSR-011 WALTHAM, Mass., Feb. 14, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) an oncology-focused biopharmaceutical company today reported f...
2/11/2013 WALTHAM, Mass., Feb. 11, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) will announce its fourth quarter and year end 2012 financial results on Thursday, February 14th, 2013, before the opening of the U.S. financial markets. TESARO's senior management will host a conference call and live webcast on Thursday, February 14th, 2013, at 8:00 a.m. E...
2/06/2013 WALTHAM, Mass., Feb. 6, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that Lonnie Moulder, Chief Executive Officer, and Mary Lynne Hedley, Ph.D., President and Chief Scientific Officer, will present at the Leerink Swann Global Healthcare Conferenceat the Waldorf Astoria Hotel in New York on Thursday, February 14, 2013 at 11:00...
11/29/2012 WALTHAM, Mass., Nov. 29, 2012 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that Lonnie Moulder, Chief Executive Officer, and Mary Lynne Hedley, Ph.D., President and Chief Scientific Officer, will present at the Deutsche Bank 2012 dbAccess BioFEST at the Four Seasons Hotel in Boston on Monday, December 3, 2012 at 3:25 p.m. EDT. ...
11/01/2012 WALTHAM, Mass., Nov. 1, 2012 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that the first clinical trial of its proprietary Anaplastic Lymphoma Kinase (ALK) inhibitor, TSR-011, has commenced with the dosing of the first patient at the Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare, a partnership between Sc...
10/25/2012 Continued Enrollment for the Global Registration Program for RolapitantAnnounced Clearance of Investigational New Drug Application for TSR-011Appointed Robert E. Martell, M.D., Ph.D., as Chief Medical Officer WALTHAM, Mass., Oct. 25, 2012 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today report...
10/16/2012 WALTHAM, Mass., Oct. 16, 2012 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) will announce its third quarter 2012 financial results on Thursday, October 25th, 2012, after the close of the U.S. financial markets. TESARO's senior management will host a conference call and live audio webcast on Thursday, October 25th, 2012, at 4:30 p.m. ET to discuss ...
10/02/2012 WALTHAM, Mass., Oct. 2, 2012 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that the Investigational New Drug (IND) application for TSR-011, an orally available ALK inhibitor (targeted anti-cancer agent) has become effective. The Company plans to dose the first patient in a Phase 1/2 clinical study within the next few months.  F...
9/04/2012 WALTHAM, Mass., Sept. 4, 2012 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) today announced the appointment of Dr. Robert Martell as Chief Medical Officer. Dr. Martell is a practicing medical oncologist at Tufts Medical Center who brings extensive drug development experience to TESARO from both industry and academia. He most recently served as Ass...
9/04/2012 WALTHAM, Mass., Sept. 4, 2012 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that Lonnie Moulder, Chief Executive Officer, and Mary Lynne Hedley, Ph.D., President and Chief Scientific Officer, will present at the 2012 Morgan Stanley Global Healthcare Conference at the Grand Hyatt in New York on Monday, September 10, 2012 at 3:00 p.m...
8/29/2012 WALTHAM, Mass., Aug. 29, 2012 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) today announced that Lonnie Moulder, Chief Executive Officer, will be presenting at the Robert W. Baird 2012 Healthcare Conference at the New York Palace Hotel in New York on Thursday, September 6, 2012 at 2:00 p.m. EDT. Also, the Company announced that Mr. Moulder will be...
7/26/2012 Key Rolapitant Clinical Trial Results Presented at ASCO and MASCC MeetingsIn-Licensed Niraparib, a Potentially First and Best-in-Class PARP InhibitorRaised Over $86.8 Million in Gross Proceeds from an Initial Public Offering WALTHAM, Mass., July 26, 2012 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) an oncology-focused biopharmaceutical compa...
7/24/2012 WALTHAM, Mass., July 24, 2012 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that the underwriters of its initial public offering have partially exercised their over-allotment option for the purchase of an additional 430,183 shares of TESARO common stock. All of such shares were sold by TESARO at the initial public offering price of...
7/19/2012 WALTHAM, Mass., July 19, 2012 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) will announce its second quarter 2012 financial results on Thursday, July 26th, 2012, before the open of the U.S. financial markets. TESARO's senior management will host a conference call and live audio webcast on Thursday, July 26th, at 8:30 a.m. ET to discuss the Company...
6/27/2012 WALTHAM, Mass., June 27, 2012 (GLOBE NEWSWIRE) -- TESARO, Inc. announced today the pricing of its initial public offering of 6,000,000 shares of its common stock at a price to the public of $13.50 per share. The shares of TESARO's common stock have been approved for listing on the NASDAQ Global Select Market and are expected to begin trading tomorr...
9/06/2011
6/21/2011
3/22/2011
12/14/2010
5/26/2010 Boston, MA – May 26, 2010 – TESARO, Inc., an oncology-focused biopharmaceutical company, today announced that it has secured $60 million in start-up funding to acquire, develop and commercialize cancer therapeutics and supportive care products. Participants in a $20 million Series A financing included New Enterprise Associates (NEA) an...
Page:
...
Next Last
 
= add release to Briefcase